NLRP3 and fatty liver disease: 14-Deoxy-11,12-didehydroandrographolide partially ameliorated steatohepatitis, liver fibrosis and liver injury in high-fat, high-cholesterol diet-induced fatty liver disease by enhancing hepatic Nrf2-mediated downstream antioxidant enzyme activity and inhibiting NLRP3 inflammasome activation, which can down-regulate the expression of NLRP3, Caspase-1 and IL-1β, and this anti-inflammatory property may be achieved by inhibiting the NF-κB signaling pathway (Liu et al., 2020).